Alterations of primary fatty acid amides in serum of patients with severe mental illness

Frontiers in Bioscience - Elite

Volumn 3 E, Issue 1, 2011, Pages 308-314

  Schwarz, Emanuel ^a   Whitfield, Phil ^b   Nahnsen, Sven ^c   Wang, Lan ^a   Major, Hilary ^d   Leweke, F Markus ^e   Koethe, Dagmar ^e   Lio, Pietro ^f   Bahn, Sabine ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d WATERS CORPORATION   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Affective disorder; Blood; Endocannabinoid system; Mass spectrometry; Primary fatty acid amides; Schizophrenia; Serum

Indexed keywords

AMIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIS; ENDOCANNABINOID; FATTY ACID; HEPTADECENOIC AMIDE; LINOLEAMIDE; MYRISTIC ACID; OLEAMIDE; PALMITIC ACID; PALMITOLEIC ACID; UNCLASSIFIED DRUG; CANNABINOID; NEUROLEPTIC AGENT;

ARTICLE; BLOOD ANALYSIS; CANNABIS SMOKING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MOOD DISORDER; PARANOID SCHIZOPHRENIA; SHORT COURSE THERAPY; SLEEP; SLEEP DEPRIVATION; TIME OF FLIGHT MASS SPECTROMETRY; BIOLOGY; BLOOD; COMPARATIVE STUDY; MASS SPECTROMETRY; METABOLISM; PHYSIOLOGY; REGRESSION ANALYSIS; SCHIZOPHRENIA; STATISTICAL MODEL;

CANNABIS;

AMIDES; ANTIPSYCHOTIC AGENTS; CANNABINOIDS; CHROMATOGRAPHY, LIQUID; COMPUTATIONAL BIOLOGY; ENDOCANNABINOIDS; FATTY ACIDS; HUMANS; LEAST-SQUARES ANALYSIS; MASS SPECTROMETRY; METABOLOMICS; MODELS, STATISTICAL; MOOD DISORDERS; SCHIZOPHRENIA; SLEEP;

EID: 79957867394     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. V. Di Marzo: 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta, 1392(2-3), 153-75 (1998) (Pubitemid 28287321)
2. D. J. Spencer: Cannabis-induced psychosis. Int J Addict, 6(2), 323-6 (1971)
3. P. K. McGuire, P. Jones, I. Harvey, P. Bebbington, B. Toone, S. Lewis and R. M. Murray: Cannabis and acute psychosis. Schizophr Res, 13(2), 161-7 (1994) (Pubitemid 24330925)
4. A. Johns: Psychiatric effects of cannabis. Br J Psychiatry, 178, 116-22 (2001) (Pubitemid 32158073)
5. D. M. Semple, A. M. McIntosh and S. M. Lawrie: Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol, 19(2), 187-94 (2005) (Pubitemid 40577224)
6. B. Dean, S. Sundram, R. Bradbury, E. Scarr and D. Copolov: Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience, 103(1), 9-15 (2001) (Pubitemid 32304342)
7. K. Zavitsanou, T. Garrick and X. F. Huang: Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 28(2), 355-60 (2004) (Pubitemid 38130143)
8. K. E. Stephan, T. Baldeweg and K. J. Friston: Synaptic plasticity and dysconnection in schizophrenia. Biol Psychiatry, 59(10), 929-39 (2006) (Pubitemid 44288017)
9. H. H. Schmid and E. V. Berdyshev: Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids, 66(2-3), 363-76 (2002) (Pubitemid 34743609)
10. W. B. Mendelson and A. S. Basile: The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. Neuroreport, 10(15), 3237-9 (1999) (Pubitemid 29498428)
11. A. H. Lichtman, E. G. Hawkins, G. Griffin and B. F. Cravatt: Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther, 302(1), 73-9 (2002) (Pubitemid 34680423)
12. E. Murillo-Rodriguez, M. Giordano, R. Cabeza, S. J. Henriksen, M. Mendez Diaz, L. Navarro and O. Prospero-Garcia: Oleamide modulates memory in rats. Neurosci Lett, 313(1-2), 61-4 (2001) (Pubitemid 32973895)
13. J. Langstein, F. Hofstadter and H. Schwarz: cis-9, 10-octadecenoamide, an endogenous sleep-inducing CNS compound, inhibits lymphocyte proliferation. Res Immunol, 147(6), 389-96 (1996) (Pubitemid 26335792)
14. B. F. Cravatt, O. Prospero-Garcia, G. Siuzdak, N. B. Gilula, S. J. Henriksen, D. L. Boger and R. A. Lerner: Chemical characterization of a family of brain lipids that induce sleep. Science, 268(5216), 1506-9 (1995)
15. B. F. Cravatt, D. K. Giang, S. P. Mayfield, D. L. Boger, R. A. Lerner and N. B. Gilula: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 384(6604), 83-7 (1996) (Pubitemid 26374593)
16. D. K. Giang and B. F. Cravatt: Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci U S A, 94(6), 2238-42 (1997) (Pubitemid 27136858)
17. D. M. Lambert and V. Di Marzo: The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem, 6(8), 757-73 (1999) (Pubitemid 29399503)
18. F. M. Leweke, A. Giuffrida, U. Wurster, H. M. Emrich and D. Piomelli: Elevated endogenous cannabinoids in schizophrenia. Neuroreport, 10(8), 1665-9 (1999) (Pubitemid 29354290)
19. A. Giuffrida, F. M. Leweke, C. W. Gerth, D. Schreiber, D. Koethe, J. Faulhaber, J. Klosterkotter and D. Piomelli: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29(11), 2108-14 (2004) (Pubitemid 39486563)
20. E. Schwarz, F. M. Leweke, S. Bahn and P. Lio: Clinical bioinformatics for complex disorders: a schizophrenia case study. BMC Bioinformatics, 10 Suppl 12, S6 (2009)
21. Y. Benjamini and Y. Hochberg: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Statist. Soc. Ser. B, 57, 289-300 (1995)
22. D. Koethe, A. Giuffrida, D. Schreiber, M. Hellmich, F. Schultze-Lutter, S. Ruhrmann, J. Klosterkotter, D. Piomelli and F. M. Leweke: Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry, 194(4), 371-2 (2009)
23. F. M. Leweke, A. Giuffrida, D. Koethe, D. Schreiber, B. M. Nolden, L. Kranaster, M. A. Neatby, M. Schneider, C. W. Gerth, M. Hellmich, J. Klosterkotter and D. Piomelli: Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res, 94(1-3), 29-36 (2007) (Pubitemid 47031599)
24. G. Irmisch, D. Schlafke, W. Gierow, S. Herpertz and J. Richter: Fatty acids and sleep in depressed inpatients. Prostaglandins Leukot Essent Fatty Acids, 76(1), 1-7 (2007) (Pubitemid 46043545)
25. N. De Marchi, L. De Petrocellis, P. Orlando, F. Daniele, F. Fezza and V. Di Marzo: Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis, 2, 5 (2003)
26. G. Gobbi, F. R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M. G. Morgese, G. Debonnel, A. Duranti, A. Tontini, G. Tarzia, M. Mor, V. Trezza, S. R. Goldberg, V. Cuomo and D. Piomelli: Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A, 102(51), 18620-5 (2005) (Pubitemid 43011275)